Comparison of sIgG4 levels among allergic patients and patients during ASIT

G. Feyzkhanova (Moscow, Russian Federation), O. Smoldovskaya (Moscow, Russian Federation), S. Voloshin (Moscow, Russian Federation), L. Pavlushkina (Moscow, Russian Federation), E. Antonova (Moscow, Russian Federation), T. Filatova (Moscow, Russian Federation), A. Zasedatelev (Moscow, Russian Federation), A. Rubina (Moscow, Russian Federation)

Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures
Session: Role of IgE and interleukin (IL)-5 in Th2-cell signatures
Session type: Thematic Poster
Number: 1139
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Feyzkhanova (Moscow, Russian Federation), O. Smoldovskaya (Moscow, Russian Federation), S. Voloshin (Moscow, Russian Federation), L. Pavlushkina (Moscow, Russian Federation), E. Antonova (Moscow, Russian Federation), T. Filatova (Moscow, Russian Federation), A. Zasedatelev (Moscow, Russian Federation), A. Rubina (Moscow, Russian Federation). Comparison of sIgG4 levels among allergic patients and patients during ASIT. 1139

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Serum levels of interleukin-1α in patients affected by atopic and non atopic asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 290s
Year: 2003

Level of sECP before and after ASIT in asthma and rhinitis patients
Source: Eur Respir J 2007; 30: Suppl. 51, 622s
Year: 2007

Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009


Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009


Omalizumab decreases IgE production in patients with severe allergic asthma
Source: Annual Congress 2012 - Aspects of clinical asthma
Year: 2012


Serum GAL3 predict response in omalizumab-treated patients with severe allergic asthma: the PROXIMA study
Source: International Congress 2018 – Innovative therapies in asthma and COPD
Year: 2018



Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond
Source: Eur Respir J 2006; 28: Suppl. 50, 440s
Year: 2006

Monitoring free serum IgE in severe asthma patients treated with omalizumab
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011


Inflammatory profile of patients with allergic asthma & rhinitis versus patients with allergic rhinitis alone
Source: Annual Congress 2007 - Mechanisms of inflammation in asthma and rhinitis - from cell cultures to patients
Year: 2007


Serum levels of interleukin-18 in patients affected by allergic bronchial asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 30s
Year: 2002

Baseline inflammation in the lower airways of allergic rhinitic subjects compared to normal subjects
Source: Eur Respir J 2001; 18: Suppl. 33, 270s
Year: 2001

Monitoring free serum IgE in asthma patients treated with omalizumab
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010

Correlations between cellular and soluble markers in the treatment with new polipeptide RUZAM in patients with allergic rhinitis
Source: Eur Respir J 2005; 26: Suppl. 49, 368s
Year: 2005

The specific methods of immunotherapy in treatment of the patients with allergic seasonal rhinitis
Source: Eur Respir J 2002; 20: Suppl. 38, 507s
Year: 2002

Inflammatory markers in induced sputum of patients with allergic rhinitis in relation to exposure to pollen allergens
Source: Eur Respir J 2006; 28: Suppl. 50, 444s
Year: 2006

Specific serum IgE is associated with seasonal symptom load in children with allergic rhinitis
Source: Annual Congress 2008 - Risk factors for allergic asthma and allergic rhinitis
Year: 2008


The influence of the allergen-specific immunotherapy (ASIT) against the backdrop of an immunomodulator in patients suffering from seasonal allergic rhinitis (SAR) on the level of cytokines, IgE and IgG.
Source: Virtual Congress 2020 – New insight into the pathogenesis of chronic lung diseases: asthma, COPD and others
Year: 2020


Follow-up of patients with moderate-severe allergic asthma treated with omalizumab
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010


Improved disease control in asthmatics treated with daclizumab is not associated with changes in allergen-specific or total IgE
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005

Does allergens influence resistin levels in children with allergic rhinitis?
Source: Annual Congress 2012 - Aspects of clinical asthma
Year: 2012